These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21514150)

  • 1. Structure-activity relationship studies of novel 3-oxazolidinedione-6-naphthyl-2-pyridinones as potent and orally bioavailable EP3 receptor antagonists.
    Morales-Ramos ÁI; Li YH; Hilfiker M; Mecom JS; Eidam P; Shi D; Tseng PS; Brooks C; Zhang D; Wang N; Jaworski JP; Morrow D; Fries H; Edwards R; Jin J
    Bioorg Med Chem Lett; 2011 May; 21(10):2806-11. PubMed ID: 21514150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists.
    Li YH; Tseng PS; Evans KA; Jaworski JP; Morrow DM; Fries HE; Wu CW; Edwards RM; Jin J
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6744-7. PubMed ID: 20926294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin gene-related peptide (CGRP) receptor antagonists: investigations of a pyridinone template.
    Nguyen DN; Paone DV; Shaw AW; Burgey CS; Mosser SD; Johnston V; Salvatore CA; Leonard YM; Miller-Stein CM; Kane SA; Koblan KS; Vacca JP; Graham SL; Williams TM
    Bioorg Med Chem Lett; 2008 Jan; 18(2):755-8. PubMed ID: 18039571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
    Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists.
    Hilfiker MA; Wang N; Hou X; Du Z; Pullen MA; Nord M; Nagilla R; Fries HE; Wu CW; Sulpizio AC; Jaworski JP; Morrow D; Edwards RM; Jin J
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4292-5. PubMed ID: 19487124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
    Cox JM; Chu HD; Yang C; Shen HC; Wu Z; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1681-4. PubMed ID: 24630411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
    Imada T; Cho N; Imaeda T; Hayase Y; Sasaki S; Kasai S; Harada M; Matsumoto H; Endo S; Suzuki N; Furuya S
    J Med Chem; 2006 Jun; 49(13):3809-25. PubMed ID: 16789738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H
    Zhang M; Tang L; Jiang L; Wei J; Hu Y; Sheng R
    Eur J Med Chem; 2021 Feb; 212():113096. PubMed ID: 33395621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
    Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
    J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.
    Jin Q; Nie H; McCleland BW; Widdowson KL; Palovich MR; Elliott JD; Goodman RM; Burman M; Sarau HM; Ward KW; Nord M; Orr BM; Gorycki PD; Busch-Petersen J
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4375-8. PubMed ID: 15357956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
    Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
    J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists.
    Nakamura M; Kurihara H; Suzuki G; Mitsuya M; Ohkubo M; Ohta H
    Bioorg Med Chem Lett; 2010 Jan; 20(2):726-9. PubMed ID: 20005101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of physicochemical properties of pyridone-based EP3 receptor antagonists.
    Zhang X; Zhu B; Guo L; Bakaj I; Rankin M; Ho G; Kauffman J; Lee SP; Norquay L; Macielag M
    Bioorg Med Chem Lett; 2021 Sep; 47():128172. PubMed ID: 34091043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
    Smith ND; Poon SF; Huang D; Green M; King C; Tehrani L; Roppe JR; Chung J; Chapman DP; Cramer M; Cosford ND
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5481-4. PubMed ID: 15482908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain.
    Bennett CE; Burnett DA; Greenlee WJ; Knutson CE; Korakas P; Li C; Tulshian D; Wu WL; Bertorelli R; Fredduzzi S; Grilli M; Lozza G; Reggiani A; Veltri A
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1575-8. PubMed ID: 22266036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3'-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one as a novel, potent, selective, and orally bioavailable ligand.
    Tatsumi R; Fujio M; Satoh H; Katayama J; Takanashi S; Hashimoto K; Tanaka H
    J Med Chem; 2005 Apr; 48(7):2678-86. PubMed ID: 15801858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists.
    Jin J; Morales-Ramos A; Eidam P; Mecom J; Li Y; Brooks C; Hilfiker M; Zhang D; Wang N; Shi D; Tseng PS; Wheless K; Budzik B; Evans K; Jaworski JP; Jugus J; Leon L; Wu C; Pullen M; Karamshi B; Rao P; Ward E; Laping N; Evans C; Leach C; Holt D; Su X; Morrow D; Fries H; Thorneloe K; Edwards R
    ACS Med Chem Lett; 2010 Oct; 1(7):316-20. PubMed ID: 24900213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and the 5-HT6 receptor antagonistic effect of 3-arylsulfonylamino-5,6-dihydro-6-substituted pyrazolo[3,4]pyridinones for neuropathic pain treatment.
    Devegowda VN; Hong JR; Cho S; Lim EJ; Choo H; Keum G; Rhim H; Nam G
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4696-700. PubMed ID: 23820387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.
    Zhang YM; Fan X; Chakaravarty D; Xiang B; Scannevin RH; Huang Z; Ma J; Burke SL; Karnachi P; Rhodes KJ; Jackson PF
    Bioorg Med Chem Lett; 2008 Jan; 18(1):409-13. PubMed ID: 17981034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.
    Xu J; Wei L; Mathvink R; Edmondson SD; Mastracchio A; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Petrov A; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1346-9. PubMed ID: 16332437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.